[{"indications": "Indications\u00a0all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Valproate", "SODIUM VALPROATE", "Modified release"], "cautions": "Cautions\u00a0monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium; interactions:  see  Interactions in section 4.8.1 and Appendix 1 (valproate)Liver toxicity\u00a0Liver dysfunction (including fatal\r\nhepatic failure) has occurred in association with valproate (especially\r\nin children under 3 years and in those\r\nwith metabolic or degenerative\r\ndisorders, organic brain disease or severe seizure disorders associated with mental\r\nretardation) usually in first 6 months and usually involving\r\nmultiple antiepileptic therapy. Raised liver enzymes\r\nduring valproate treatment are usually transient but patients should\r\nbe reassessed clinically and liver function (including prothrombin\r\ntime) monitored until return to normal\u2014discontinue if abnormally prolonged prothrombin time (particularly\r\nin association with other relevant abnormalities).Blood or hepatic disorders\u00a0Patients or their carers should be told how to recognise signs and\r\nsymptoms of blood or liver disorders and advised to seek immediate\r\nmedical attention if symptoms developPancreatitis\u00a0Patients or their carers\r\nshould be told how to recognise signs and symptoms of pancreatitis\r\nand advised to seek immediate medical attention if symptoms such as\r\nabdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly); less frequently increased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis; rarely hepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash; very rarely pancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions); also reported menstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201160.htm", "doses": ["Epilepsy, by mouth, initially 600\u00a0mg\r\ndaily in 1\u20132 divided doses, increased gradually (in steps of 150\u2013300\u00a0mg)\r\nevery 3 days; usual maintenance dose 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily),\r\nmax. 2.5\u00a0g daily; child 1 month\u201312\r\nyears, initially 10\u201315\u00a0mg/kg (max. 600\u00a0mg) daily in 1\u20132 divided doses;\r\nusual maintenance dose 25\u201330\u00a0mg/kg daily in 2 divided doses", "Initiation of valproate treatment by intravenous administration, adult and child over 12 years, initially 10\u00a0mg/kg (usually 400\u2013800\u00a0mg) by intravenous injection (over 3\u20135 minutes) followed by intravenous infusion or intravenous\r\ninjection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up\r\nto max. 2.5\u00a0g daily; usual range 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily); child 1 month\u201312 years, 10\u00a0mg/kg by intravenous\r\ninjection (over 3\u20135 minutes) followed by intravenous\r\ninfusion or intravenous injection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up to usual range 20\u201340\u00a0mg/kg\r\ndaily (doses above 40\u00a0mg/kg daily monitor clinical chemistry and haematological\r\nparameters)", "Continuation of valproate treatment by intravenous injection (over 3\u20135 minutes) or intravenous infusion in 2\u20134 divided doses, or by continuous intravenous infusion, same as established oral daily dose", "Migraine prophylaxis [unlicensed], by mouth, initially 200\u00a0mg twice daily, increased if necessary to 1.2\u20131.5\u00a0g\r\ndaily in divided doses", "Mania, see under Episenta\u00ae", "Granules may be mixed with soft food\r\nor drink that is cold or at room temperature, and swallowed immediately\r\nwithout chewing", "Name[Epilim Chronosphere\u00ae (Sanofi-Aventis) ] Granules, m/r, sodium valproate\r\n50\u00a0mg (as sodium valproate and valproic acid), net price 30-sachet\r\npack = \u00a330.00; 100\u00a0mg, 30-sachet pack = \u00a330.00; 250\u00a0mg, 30-sachet\r\npack = \u00a330.00; 500\u00a0mg, 30-sachet pack = \u00a330.00; 750\u00a0mg, 30-sachet\r\npack = \u00a330.00; 1\u00a0g, 30-sachet pack = \u00a330.00. \r\n    Label:\r\n    8, 21, 25, counselling, administration, pancreatitis, blood, or hepatic disorder symptoms (see above), driving\r\n(see notes above)Dose\u00a0epilepsy, adult and child, as above to the nearest whole 50-mg sachet;\r\ntotal daily dose given in 1\u20132 divided dosesCounselling\u00a0Granules may be mixed with soft food\r\nor drink that is cold or at room temperature, and swallowed immediately\r\nwithout chewing"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported"}, {"indications": "Indications\u00a0all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE Oral", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Valproate", "SODIUM VALPROATE", "Oral"], "cautions": "Cautions\u00a0monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium; interactions:  see  Interactions in section 4.8.1 and Appendix 1 (valproate)Liver toxicity\u00a0Liver dysfunction (including fatal\r\nhepatic failure) has occurred in association with valproate (especially\r\nin children under 3 years and in those\r\nwith metabolic or degenerative\r\ndisorders, organic brain disease or severe seizure disorders associated with mental\r\nretardation) usually in first 6 months and usually involving\r\nmultiple antiepileptic therapy. Raised liver enzymes\r\nduring valproate treatment are usually transient but patients should\r\nbe reassessed clinically and liver function (including prothrombin\r\ntime) monitored until return to normal\u2014discontinue if abnormally prolonged prothrombin time (particularly\r\nin association with other relevant abnormalities).Blood or hepatic disorders\u00a0Patients or their carers should be told how to recognise signs and\r\nsymptoms of blood or liver disorders and advised to seek immediate\r\nmedical attention if symptoms developPancreatitis\u00a0Patients or their carers\r\nshould be told how to recognise signs and symptoms of pancreatitis\r\nand advised to seek immediate medical attention if symptoms such as\r\nabdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly); less frequently increased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis; rarely hepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash; very rarely pancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions); also reported menstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3601.htm", "doses": ["Epilepsy, by mouth, initially 600\u00a0mg\r\ndaily in 1\u20132 divided doses, increased gradually (in steps of 150\u2013300\u00a0mg)\r\nevery 3 days; usual maintenance dose 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily),\r\nmax. 2.5\u00a0g daily; child 1 month\u201312\r\nyears, initially 10\u201315\u00a0mg/kg (max. 600\u00a0mg) daily in 1\u20132 divided doses;\r\nusual maintenance dose 25\u201330\u00a0mg/kg daily in 2 divided doses", "Initiation of valproate treatment by intravenous administration, adult and child over 12 years, initially 10\u00a0mg/kg (usually 400\u2013800\u00a0mg) by intravenous injection (over 3\u20135 minutes) followed by intravenous infusion or intravenous\r\ninjection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up\r\nto max. 2.5\u00a0g daily; usual range 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily); child 1 month\u201312 years, 10\u00a0mg/kg by intravenous\r\ninjection (over 3\u20135 minutes) followed by intravenous\r\ninfusion or intravenous injection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up to usual range 20\u201340\u00a0mg/kg\r\ndaily (doses above 40\u00a0mg/kg daily monitor clinical chemistry and haematological\r\nparameters)", "Continuation of valproate treatment by intravenous injection (over 3\u20135 minutes) or intravenous infusion in 2\u20134 divided doses, or by continuous intravenous infusion, same as established oral daily dose", "Migraine prophylaxis [unlicensed], by mouth, initially 200\u00a0mg twice daily, increased if necessary to 1.2\u20131.5\u00a0g\r\ndaily in divided doses", "Mania, see under Episenta\u00ae", "Name[Epilim\u00ae (Sanofi-Aventis) ] Tablets (crushable), scored, sodium\r\nvalproate 100\u00a0mg, net price 100-tab pack = \u00a35.60. \r\n    Label:\r\n    8, 21, counselling, pancreatitis, blood, or hepatic disorder\r\nsymptoms (see above), driving (see notes above)\nTablets, e/c, lilac, sodium valproate\r\n200\u00a0mg, net price 100-tab pack = \u00a37.70; 500\u00a0mg, 100-tab pack = \u00a319.25. \r\n    Label:\r\n    5, 8, 25, counselling, pancreatitis, blood, or\r\nhepatic disorder symptoms (see above), driving (see notes above)\nLiquid, red, sugar-free, sodium valproate 200\u00a0mg/5\u00a0mL, net price 300-mL pack = \u00a39.33. \r\n    Label:\r\n    8, 21, counselling, pancreatitis, blood, or\r\nhepatic disorder symptoms (see above), driving (see notes above)\nSyrup, red, sodium valproate 200\u00a0mg/5\u00a0mL, net price 300-mL pack = \u00a37.78. \r\n    Label:\r\n    8, 21, counselling, pancreatitis, blood, or hepatic disorder symptoms (see above), driving (see notes above)Note\u00a0May be diluted, preferably in Syrup BP; use\r\nwithin 14 days "], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported"}, {"indications": "Indications\u00a0all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Valproate", "SODIUM VALPROATE"], "cautions": "Cautions\u00a0monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium; interactions:  see  Interactions in section 4.8.1 and Appendix 1 (valproate)Liver toxicity\u00a0Liver dysfunction (including fatal\r\nhepatic failure) has occurred in association with valproate (especially\r\nin children under 3 years and in those\r\nwith metabolic or degenerative\r\ndisorders, organic brain disease or severe seizure disorders associated with mental\r\nretardation) usually in first 6 months and usually involving\r\nmultiple antiepileptic therapy. Raised liver enzymes\r\nduring valproate treatment are usually transient but patients should\r\nbe reassessed clinically and liver function (including prothrombin\r\ntime) monitored until return to normal\u2014discontinue if abnormally prolonged prothrombin time (particularly\r\nin association with other relevant abnormalities).Blood or hepatic disorders\u00a0Patients or their carers should be told how to recognise signs and\r\nsymptoms of blood or liver disorders and advised to seek immediate\r\nmedical attention if symptoms developPancreatitis\u00a0Patients or their carers\r\nshould be told how to recognise signs and symptoms of pancreatitis\r\nand advised to seek immediate medical attention if symptoms such as\r\nabdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly); less frequently increased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis; rarely hepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash; very rarely pancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions); also reported menstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/130021.htm", "doses": ["Epilepsy, by mouth, initially 600\u00a0mg\r\ndaily in 1\u20132 divided doses, increased gradually (in steps of 150\u2013300\u00a0mg)\r\nevery 3 days; usual maintenance dose 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily),\r\nmax. 2.5\u00a0g daily; child 1 month\u201312\r\nyears, initially 10\u201315\u00a0mg/kg (max. 600\u00a0mg) daily in 1\u20132 divided doses;\r\nusual maintenance dose 25\u201330\u00a0mg/kg daily in 2 divided doses", "Initiation of valproate treatment by intravenous administration, adult and child over 12 years, initially 10\u00a0mg/kg (usually 400\u2013800\u00a0mg) by intravenous injection (over 3\u20135 minutes) followed by intravenous infusion or intravenous\r\ninjection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up\r\nto max. 2.5\u00a0g daily; usual range 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily); child 1 month\u201312 years, 10\u00a0mg/kg by intravenous\r\ninjection (over 3\u20135 minutes) followed by intravenous\r\ninfusion or intravenous injection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up to usual range 20\u201340\u00a0mg/kg\r\ndaily (doses above 40\u00a0mg/kg daily monitor clinical chemistry and haematological\r\nparameters)", "Continuation of valproate treatment by intravenous injection (over 3\u20135 minutes) or intravenous infusion in 2\u20134 divided doses, or by continuous intravenous infusion, same as established oral daily dose", "Migraine prophylaxis [unlicensed], by mouth, initially 200\u00a0mg twice daily, increased if necessary to 1.2\u20131.5\u00a0g\r\ndaily in divided doses", "Mania, see under Episenta\u00ae"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported"}, {"indications": "Indications\u00a0all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE Valproic acid", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Valproate", "SODIUM VALPROATE", "Valproic acid"], "cautions": "Cautions\u00a0monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium; interactions:  see  Interactions in section 4.8.1 and Appendix 1 (valproate)Liver toxicity\u00a0Liver dysfunction (including fatal\r\nhepatic failure) has occurred in association with valproate (especially\r\nin children under 3 years and in those\r\nwith metabolic or degenerative\r\ndisorders, organic brain disease or severe seizure disorders associated with mental\r\nretardation) usually in first 6 months and usually involving\r\nmultiple antiepileptic therapy. Raised liver enzymes\r\nduring valproate treatment are usually transient but patients should\r\nbe reassessed clinically and liver function (including prothrombin\r\ntime) monitored until return to normal\u2014discontinue if abnormally prolonged prothrombin time (particularly\r\nin association with other relevant abnormalities).Blood or hepatic disorders\u00a0Patients or their carers should be told how to recognise signs and\r\nsymptoms of blood or liver disorders and advised to seek immediate\r\nmedical attention if symptoms developPancreatitis\u00a0Patients or their carers\r\nshould be told how to recognise signs and symptoms of pancreatitis\r\nand advised to seek immediate medical attention if symptoms such as\r\nabdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly); less frequently increased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis; rarely hepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash; very rarely pancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions); also reported menstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200958.htm", "doses": ["Epilepsy, by mouth, initially 600\u00a0mg\r\ndaily in 1\u20132 divided doses, increased gradually (in steps of 150\u2013300\u00a0mg)\r\nevery 3 days; usual maintenance dose 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily),\r\nmax. 2.5\u00a0g daily; child 1 month\u201312\r\nyears, initially 10\u201315\u00a0mg/kg (max. 600\u00a0mg) daily in 1\u20132 divided doses;\r\nusual maintenance dose 25\u201330\u00a0mg/kg daily in 2 divided doses", "Initiation of valproate treatment by intravenous administration, adult and child over 12 years, initially 10\u00a0mg/kg (usually 400\u2013800\u00a0mg) by intravenous injection (over 3\u20135 minutes) followed by intravenous infusion or intravenous\r\ninjection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up\r\nto max. 2.5\u00a0g daily; usual range 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily); child 1 month\u201312 years, 10\u00a0mg/kg by intravenous\r\ninjection (over 3\u20135 minutes) followed by intravenous\r\ninfusion or intravenous injection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up to usual range 20\u201340\u00a0mg/kg\r\ndaily (doses above 40\u00a0mg/kg daily monitor clinical chemistry and haematological\r\nparameters)", "Continuation of valproate treatment by intravenous injection (over 3\u20135 minutes) or intravenous infusion in 2\u20134 divided doses, or by continuous intravenous infusion, same as established oral daily dose", "Migraine prophylaxis [unlicensed], by mouth, initially 200\u00a0mg twice daily, increased if necessary to 1.2\u20131.5\u00a0g\r\ndaily in divided doses", "Mania, see under Episenta\u00ae", "Name[Depakote\u00ae (Sanofi-Aventis) ] Section 4.2.3 (bipolar disorder)"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported"}, {"indications": "Indications\u00a0all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE Parenteral", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.8 Antiepileptic drugs", "4.8.1 Control of the epilepsies", "Valproate", "SODIUM VALPROATE", "Parenteral"], "cautions": "Cautions\u00a0monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium; interactions:  see  Interactions in section 4.8.1 and Appendix 1 (valproate)Liver toxicity\u00a0Liver dysfunction (including fatal\r\nhepatic failure) has occurred in association with valproate (especially\r\nin children under 3 years and in those\r\nwith metabolic or degenerative\r\ndisorders, organic brain disease or severe seizure disorders associated with mental\r\nretardation) usually in first 6 months and usually involving\r\nmultiple antiepileptic therapy. Raised liver enzymes\r\nduring valproate treatment are usually transient but patients should\r\nbe reassessed clinically and liver function (including prothrombin\r\ntime) monitored until return to normal\u2014discontinue if abnormally prolonged prothrombin time (particularly\r\nin association with other relevant abnormalities).Blood or hepatic disorders\u00a0Patients or their carers should be told how to recognise signs and\r\nsymptoms of blood or liver disorders and advised to seek immediate\r\nmedical attention if symptoms developPancreatitis\u00a0Patients or their carers\r\nshould be told how to recognise signs and symptoms of pancreatitis\r\nand advised to seek immediate medical attention if symptoms such as\r\nabdominal pain, nausea, or vomiting develop; discontinue if pancreatitis is diagnosed", "side-effects": "Side-effects\u00a0nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly); less frequently increased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis; rarely hepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash; very rarely pancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions); also reported menstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3602.htm", "doses": ["Epilepsy, by mouth, initially 600\u00a0mg\r\ndaily in 1\u20132 divided doses, increased gradually (in steps of 150\u2013300\u00a0mg)\r\nevery 3 days; usual maintenance dose 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily),\r\nmax. 2.5\u00a0g daily; child 1 month\u201312\r\nyears, initially 10\u201315\u00a0mg/kg (max. 600\u00a0mg) daily in 1\u20132 divided doses;\r\nusual maintenance dose 25\u201330\u00a0mg/kg daily in 2 divided doses", "Initiation of valproate treatment by intravenous administration, adult and child over 12 years, initially 10\u00a0mg/kg (usually 400\u2013800\u00a0mg) by intravenous injection (over 3\u20135 minutes) followed by intravenous infusion or intravenous\r\ninjection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up\r\nto max. 2.5\u00a0g daily; usual range 1\u20132\u00a0g daily (20\u201330\u00a0mg/kg daily); child 1 month\u201312 years, 10\u00a0mg/kg by intravenous\r\ninjection (over 3\u20135 minutes) followed by intravenous\r\ninfusion or intravenous injection (over 3\u20135 minutes) in 2\u20134 divided doses or by continuous intravenous infusion up to usual range 20\u201340\u00a0mg/kg\r\ndaily (doses above 40\u00a0mg/kg daily monitor clinical chemistry and haematological\r\nparameters)", "Continuation of valproate treatment by intravenous injection (over 3\u20135 minutes) or intravenous infusion in 2\u20134 divided doses, or by continuous intravenous infusion, same as established oral daily dose", "Migraine prophylaxis [unlicensed], by mouth, initially 200\u00a0mg twice daily, increased if necessary to 1.2\u20131.5\u00a0g\r\ndaily in divided doses", "Mania, see under Episenta\u00ae", "Name[Epilim\u00ae Intravenous (Sanofi-Aventis) ] Injection, powder for reconstitution,\r\nsodium valproate, net price 400-mg vial (with 4-mL amp water for injections)\r\n= \u00a311.58"], "pregnancy": "Pregnancy\u00a0see Pregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported"}]